by John Conrad | Oct 30, 2024 | Member News, NewsBrief
Pathos AI, a Chicago-based biotech startup, has secured $62 million in Series C funding to advance its AI-driven approach to drug development, according to a Tuesday press release. The funding news, also covered by Katherine Davis of Crain’s Chicago Business and...
by John Conrad | Sep 26, 2024 | Member News
ARCH Venture Partners, the Chicago-based venture capital firm known for its bold bets in biotechnology, has once again demonstrated its commitment to driving healthcare innovation. The firm announced on September 26, 2024, that it has raised $3 billion for its...
by John Conrad | Jul 17, 2024 | NewsBrief
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based...
by John Conrad | Jun 27, 2024 | NewsBrief
Tempus AI, Inc. (NASDAQ: TEM) has achieved a significant milestone in the field of artificial intelligence and precision medicine. The company recently announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative...
by John Conrad | Jun 14, 2024 | NewsBrief
Congratulations to iBIO member Tempus AI and its founder, Eric Lefkofsky, on their remarkable achievement! We are thrilled to announce that Tempus AI, a trailblazing precision-medicine startup, is set to make its highly anticipated debut on the stock market this...
